Intellectual Property
IPMD and Nixon Peabody, a global law firm, have signed an agreement for Nixon Peabody to serve as IPMD’s intellectual property counsel. Together with IPMD, Nixon Peabody will formulate and execute a strategy to protect IPMD’s innovative technology with a combination of patents, trade secrets, and copyrights. IPMD’s proprietary technologies that will be protected include its artificial intelligence disease diagnostics platforms and highly sophisticated point of care disease screening and diagnostics medical device.
IPMD has strong confidence on Nixon Peabody. In April 2015, Intellectual Asset Management (IAM) magazine ranked Nixon Peabody among the top law firms for securing high-quality patents on behalf of its clients. IAM magazine ranked Nixon Peabody #7 overall in its ratings, which are calculated using Ocean Tomo’s OTR metric. Ocean Tomo gives a quality score to each patent granted over the past three years. Additionally, Nixon Peabody received a number of top-ten rankings in specific industries, including: #1 in Information Technology, #5 in Healthcare (pharma/bio), #6 in Consumer Electronics/Discretionary, and #7 in Industrials. Nixon Peabody has a history of obtaining high-quality patents for its clients. In addition to these IAM magazine rankings, Nixon Peabody’s patents practice has also been recognized by Managing IP magazine for securing “the highest quality patents” for clients across all industries. Nixon Peabody is also selected as the Law Firm of The Year” in the 2016 edition of U.S. News-Best Lawyers “Best Law Firms” in Healthcare Sector.
IPMD’s intellectual property is based on complex combination of BioTech and InfoTech, and Nixon Peabody is the ideal firm to protect its technology. Erik Birkeneder, IPMD’s IP counsel at Nixon Peabody, has a Master’s in Biomedical Engineering and has deep experience in patenting these crossover technologies.
Nixon Peabody will also serve as IPMD’s General Counsel. IPMD’s CEO & President, Min Lee will be included into Nixon Peabody’s Capital Connector Program, to provide access to funding and human resources through Nixon Peabody’s private equity network
IPMD has strong confidence on Nixon Peabody. In April 2015, Intellectual Asset Management (IAM) magazine ranked Nixon Peabody among the top law firms for securing high-quality patents on behalf of its clients. IAM magazine ranked Nixon Peabody #7 overall in its ratings, which are calculated using Ocean Tomo’s OTR metric. Ocean Tomo gives a quality score to each patent granted over the past three years. Additionally, Nixon Peabody received a number of top-ten rankings in specific industries, including: #1 in Information Technology, #5 in Healthcare (pharma/bio), #6 in Consumer Electronics/Discretionary, and #7 in Industrials. Nixon Peabody has a history of obtaining high-quality patents for its clients. In addition to these IAM magazine rankings, Nixon Peabody’s patents practice has also been recognized by Managing IP magazine for securing “the highest quality patents” for clients across all industries. Nixon Peabody is also selected as the Law Firm of The Year” in the 2016 edition of U.S. News-Best Lawyers “Best Law Firms” in Healthcare Sector.
IPMD’s intellectual property is based on complex combination of BioTech and InfoTech, and Nixon Peabody is the ideal firm to protect its technology. Erik Birkeneder, IPMD’s IP counsel at Nixon Peabody, has a Master’s in Biomedical Engineering and has deep experience in patenting these crossover technologies.
Nixon Peabody will also serve as IPMD’s General Counsel. IPMD’s CEO & President, Min Lee will be included into Nixon Peabody’s Capital Connector Program, to provide access to funding and human resources through Nixon Peabody’s private equity network
